Rationale and Development of an OCT-Based Method for Detection of Glaucomatous Optic Neuropathy.
Journal
Journal of glaucoma
ISSN: 1536-481X
Titre abrégé: J Glaucoma
Pays: United States
ID NLM: 9300903
Informations de publication
Date de publication:
01 06 2022
01 06 2022
Historique:
received:
17
10
2021
accepted:
08
02
2022
pubmed:
28
2
2022
medline:
7
6
2022
entrez:
27
2
2022
Statut:
ppublish
Résumé
A specific, sensitive, and intersubjectively verifiable definition of disease for clinical care and research remains an important unmet need in the field of glaucoma. Using an iterative, consensus-building approach and employing pilot data, an optical coherence tomography (OCT)-based method to aid in the detection of glaucomatous optic neuropathy was sought to address this challenge. To maximize the chance of success, we utilized all available information from the OCT circle and cube scans, applied both quantitative and semiquantitative data analysis methods, and aimed to limit the use of perimetry to cases where it is absolutely necessary. The outcome of this approach was an OCT-based method for the diagnosis of glaucomatous optic neuropathy that did not require the use of perimetry for initial diagnosis. A decision tree was devised for testing and implementation in clinical practice and research that can be used by reading centers, researchers, and clinicians. While initial pilot data were encouraging, future testing and validation will be needed to establish its utility in clinical practice, as well as for research.
Identifiants
pubmed: 35220387
doi: 10.1097/IJG.0000000000002005
pii: 00061198-202206000-00002
pmc: PMC9167228
mid: NIHMS1778900
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
375-381Subventions
Organisme : NEI NIH HHS
ID : R01 EY002115
Pays : United States
Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure: J.M.L. received instrument support from Carl Zeiss Meditech Inc. and Heidelberg Engineering GmbH. D.C.H. received equipment and grant funding from Heidelberg Engineering and Topcon Inc.; received grant funding from Novartis. The remaining authors declare no conflict of interest.
Références
Acta Ophthalmol. 2016 May;94(3):e211-9
pubmed: 26132774
Invest Ophthalmol Vis Sci. 2011 Feb 16;52(2):940-6
pubmed: 20881293
Am J Ophthalmol. 2017 Feb;174:1-8
pubmed: 27818206
Transl Vis Sci Technol. 2016 Nov 08;5(6):4
pubmed: 27847691
Curr Opin Ophthalmol. 2020 Mar;31(2):85-90
pubmed: 31922980
IEEE Trans Biomed Eng. 2021 Aug;68(8):2456-2466
pubmed: 33290209
PLoS One. 2017 Oct 27;12(10):e0186793
pubmed: 29077730
Am J Ophthalmol. 2021 Mar;223:119-128
pubmed: 32777374
Arch Ophthalmol. 2009 Sep;127(9):1136-45
pubmed: 19752422
J Glaucoma. 2017 Nov;26(11):995-1000
pubmed: 28858152
Prog Retin Eye Res. 2017 Mar;57:46-75
pubmed: 28012881
Lancet Digit Health. 2019 Aug;1(4):e151-e152
pubmed: 33323181
Am J Ophthalmol. 2019 Mar;199:193-199
pubmed: 30471242
Arch Ophthalmol. 1989 Jan;107(1):81-6
pubmed: 2642703
Invest Ophthalmol Vis Sci. 2010 Nov;51(11):5724-30
pubmed: 20574014
Am J Ophthalmol. 2002 Jan;133(1):19-28
pubmed: 11755836
Curr Opin Ophthalmol. 1995 Apr;6(2):46-51
pubmed: 10150857
Transl Vis Sci Technol. 2020 Oct 19;9(11):22
pubmed: 33150048
Am J Ophthalmol. 2016 Aug;168:40-51
pubmed: 27173372
Prog Retin Eye Res. 2013 Jan;32:1-21
pubmed: 22995953
Invest Ophthalmol Vis Sci. 2019 Oct 1;60(13):4241-4248
pubmed: 31618760
Transl Vis Sci Technol. 2015 Nov 30;4(6):4
pubmed: 26644964
Ophthalmology. 2000 Oct;107(10):1809-15
pubmed: 11013178
J Glaucoma. 2017 Dec;26(12):1086-1094
pubmed: 29045329
Ophthalmology. 2010 Sep;117(9):1674-83
pubmed: 20633931
Invest Ophthalmol Vis Sci. 2018 Feb 1;59(2):788-791
pubmed: 29392325
Medicine (Baltimore). 2017 Jun;96(24):e6855
pubmed: 28614218
J Glaucoma. 2018 Nov;27(11):971-975
pubmed: 30113513
Transl Vis Sci Technol. 2020 Mar 18;9(4):14
pubmed: 32818101
Invest Ophthalmol Vis Sci. 2014 Oct 23;55(12):7814-20
pubmed: 25342615
Invest Ophthalmol Vis Sci. 2010 Nov;51(11):5685-9
pubmed: 20538998
Transl Vis Sci Technol. 2020 Jul 22;9(2):42
pubmed: 32855846
Invest Ophthalmol Vis Sci. 2015 Jul;56(8):4857-64
pubmed: 25829417
Jpn J Ophthalmol. 2010 Jan;54(1):43-7
pubmed: 20151275
Prog Retin Eye Res. 2022 Sep;90:101052
pubmed: 35216894
Ophthalmology. 2017 Oct;124(10):1449-1456
pubmed: 28551166
Br J Ophthalmol. 2002 Feb;86(2):238-42
pubmed: 11815354
J Glaucoma. 2018 Aug;27(8):657-664
pubmed: 29917000
Arch Ophthalmol. 2005 Sep;123(9):1188-97
pubmed: 16157798
Arch Ophthalmol. 2000 Sep;118(9):1187-94
pubmed: 10980763
Br J Ophthalmol. 2021 Jun;105(6):789-793
pubmed: 32699052
Am J Ophthalmol. 2015 Mar;159(3):565-76.e2
pubmed: 25498118
Graefes Arch Clin Exp Ophthalmol. 2014 Feb;252(2):321-30
pubmed: 24337431
JAMA Ophthalmol. 2014 Mar;132(3):291-7
pubmed: 24407153
Eur J Ophthalmol. 2020 Jul;30(4):706-713
pubmed: 30871370
Jpn J Ophthalmol. 2014 Mar;58(2):188-96
pubmed: 24442888
Transl Vis Sci Technol. 2016 Apr 14;5(2):15
pubmed: 27134774
Eye (Lond). 2021 Nov;35(11):2973-2982
pubmed: 33414534
J Glaucoma. 1996 Dec;5(6):384-9
pubmed: 8946294
Am J Ophthalmol. 2016 Jan;161:150-9
pubmed: 26476213